172 related articles for article (PubMed ID: 37828980)
41. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
Front Immunol; 2022; 13():873789. PubMed ID: 35572515
[TBL] [Abstract][Full Text] [Related]
42. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
[TBL] [Abstract][Full Text] [Related]
43. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
46. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Havard R; Stephens DM
Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
[TBL] [Abstract][Full Text] [Related]
47. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
48. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
Sun Z; Xie C; Liu H; Yuan X
Front Immunol; 2022; 13():778192. PubMed ID: 35154102
[TBL] [Abstract][Full Text] [Related]
49. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
50. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
51. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
[TBL] [Abstract][Full Text] [Related]
52. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
Br J Haematol; 2022 Sep; 198(5):838-846. PubMed ID: 35765220
[TBL] [Abstract][Full Text] [Related]
53. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
54. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
[TBL] [Abstract][Full Text] [Related]
55. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
56. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
[TBL] [Abstract][Full Text] [Related]
57. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
58. [Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].
Hanajiri R; Furukawa K; Nakashima M; Ushijima Y; Shimada K; Ishikawa Y; Terakura S; Murata M; Kiyoi H
Rinsho Ketsueki; 2023; 64(3):167-174. PubMed ID: 37019669
[TBL] [Abstract][Full Text] [Related]
59. The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
Galli E; Bellesi S; Pansini I; Di Cesare G; Iacovelli C; Malafronte R; Maiolo E; Chiusolo P; Sica S; Sorà F; Hohaus S
Br J Haematol; 2023 Nov; 203(4):564-570. PubMed ID: 37789569
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
